60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharmaceuticals entered into an exclusive option agreement with the Florida State University Research Foundation to license IP for castanospermine targeting tick-borne diseases. The agreement covers Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease, giving the company time to formulate a commercialization strategy.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.